AltaCorp Captial Sticks to Their Buy Rating for GW Pharma (GWPH)

By Austin Angelo

AltaCorp Captial analyst David Kideckel reiterated a Buy rating on GW Pharma (GWPHResearch Report) yesterday and set a price target of $221. The company’s shares opened today at $185.54, close to its 52-week high of $196.

Kideckel has an average return of 37.0% when recommending GW Pharma.

According to TipRanks.com, Kideckel is ranked #2145 out of 5182 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for GW Pharma with a $215.56 average price target, representing a 16.2% upside. In a report issued on May 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $229 price target.

See today’s analyst top recommended stocks >>

Based on GW Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.31 million. In comparison, last year the company had a GAAP net loss of $87.2 million.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.